Brensocatib Approval Highlights Potential of DPP1 Inhibitors for Neutrophil-Mediated Diseases: James D. Chalmers, MBChB, PhD

Brensocatib, the first FDA-approved dipeptidyl peptidase 1 (DPP1) inhibitor for non–cystic fibrosis bronchiectasis, may have broader potential for other neutrophil-driven conditions, according to James D. Chalmers, MBChB, PhD.